SOURCE: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Logo

March 30, 2016 10:29 ET

Intellect Neurosciences, Inc. Engages Benjamin D. Freilich, MD, FACS as Senior Medical Affairs Advisor for CONJUMAB-A Antibody Drug Conjugate Program

NEW YORK, NY--(Marketwired - March 30, 2016) - Intellect Neurosciences, Inc. (OTCQB: ILNS), a research-based biotechnology company focused on the discovery, development and licensing of novel disease-modifying therapeutics for the treatment and prevention of rare neurodegenerative orphan diseases with no approved therapies, announced today that it has appointed Benjamin D. Freilich, MD, FACS as Senior Medical Affairs Advisor. Dr. Freilich has agreed to assist the company in shaping and guiding the company's CONJUMAB-A antibody drug conjugate (ADC) program, and in particular, to advise the company on the design of CONJUMAB-A and future pre-clinical and clinical studies targeting Age-Related Macular Degeneration (AMD).

Dr. Freilich is certified by the American Board of Ophthalmology and is a retina specialist practicing in New Jersey with a focus on AMD. Dr. Freilich received a BA in biology with Honors from the University of Chicago. He earned his MD degree Summa Cum Laude at the State University of New York Downstate Medical Center, and did his ophthalmology residency at the Mount Sinai School of Medicine. Dr. Freilich completed a two year vitreo-retinal fellowship at the Massachusetts Eye and Ear Infirmary as well as a research fellowship at The Schepens Eye Research Institute, both of Harvard Medical School. Dr. Freilich also attended the Naval Aerospace Medicine Institute where he was certified as a US Navy Flight Surgeon. He served as a Commander in the United States Navy Reserve. Prior to entering private practice, Dr. Freilich was full time academic faculty at SUNY Downstate, and then joined the academic faculty at The Mount Sinai School of Medicine, where he continues to hold the title of Assistant Clinical Professor of Ophthalmology.

The primary focus of Dr. Freilich's private medical practice is the treatment of both atrophic and neovascular Age-Related Macular Degeneration, the dry and wet forms, respectively, of AMD. Dr. Freilich has treated several thousand patients with AMD over the course of his career and is an expert in the latest cutting edge treatments.

Elliot Maza, Chief Executive Officer, CFO and Chairman of Intellect, commented, "We are especially privileged to add Dr. Freilich to our advisory team. Dr. Freilich's experience as a prominent physician treating countless AMD patients will contribute a unique and practical perspective to our CONJUMAB research program in particular, and to all of our research programs more generally. Our lead scientific advisor, Dr. Troy Rohn, Professor, Department of Biological Sciences, Boise State University, and I are excited about working closely with Dr. Freilich to advance CONJUMAB-A for the treatment of AMD."

Dr. Freilich commented, "I am extremely excited to join the Intellect team and contribute to the company's efforts to develop a viable treatment option for patients suffering from the atrophic or dry form of AMD, which can lead to severe visual loss in many patients. At this point in time, there is no truly effective therapy for advanced atrophic AMD. Also, Intellect's potential AMD therapy might prove to be effective at preventing the neovascular form of AMD."

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. is a research-based biotechnology company focused on the discovery, development and licensing of novel disease-modifying therapeutics for the treatment and prevention of rare neurodegenerative, "orphan," diseases with no approved therapies. Our compounds under development include OX1, a high affinity, copper binding molecule that protects the body against free radicals. OX1 (renamed "SHP622") is licensed to Shire plc, which recently completed a single ascending dose and multiple ascending dose Phase 1b clinical study in 55 patients with Friedreich's Ataxia designed to evaluate the safety, tolerability, and PK/PD of SHP622. Details of the study, entitled, "A Phase 1, Randomized, Double-blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral VP 20629 in Adult Subjects with Friedreich's Ataxia," may be found at:, identifier NCT01898884. For more information, please visit

Safe Harbor Statements Regarding Forward-Looking Statements

The statements in this letter made by representatives of Intellect Neurosciences relating to matters that are not historical facts, including without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources, the continued development by Shire of SHP622 or its determination to seek Orphan Drug designation for the pharmaceutical product of SHP622 are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those discussed in Intellect's Annual Report on Form 10-K for the fiscal year ended June 30, 2015 (file no. 333-128226) filed on October 14, 2015 and Quarterly Reports on Form 10-Q (file no. 333-128226) for the periods ended September 30, 2015 and December 31, 2015, filed on November 12, 2015 and February 12, 2016, respectively.

Contact Information

  • For further information contact: 
    David Zazoff 
    MDM Worldwide Solutions, Inc.
    264 W 40th St, #602 
    New York, NY 10018
    (212) 643-0417